JAK1 and neoplasm: Several signaling pathways have been implicated in tumor-associated molecular alterations that contribute to the immune suppression of the TME, such as Kirsten rat sarcoma viral oncogene (KRAS), focal adhesion kinase (FAK), and Janus kinase-1/2 (JAK1/2).